Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Q3 2023 Earnings Presentation
11 slides from Invivyd's earnings presentation, Nov 9, 2023
Slide 1: Q3 2023 Financial Results & Business Highlights
Exhibit 99.2 INVIVYD Q3 2023 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 9, 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
AGENDA 1. Introduction/Overview − Dave Hering, Chief Executive Officer 2. CANOPY Trial & Latest VYD222 In Vitro Neutralizing Data − Pete Schmidt, M.D., Chief Medical Officer 3. Market Opportunity & Commercial Preparations − Jeremy Gowler, Chief Operating & Commercial Officer 4. Q3 Financial Review −
Slide 4: Recent Business Highlights & Key Achievements
RECENT BUSINESS HIGHLIGHTS & KEY ACHIEVEMENTS Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19 Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024 Company aims to submit an application
Slide 5: The Need to Protect Immunocompromised Individuals from COVID-19 Is Clear and Urgent
THE NEED TO PROTECT IMMUNOCOMPROMISED INDIVIDUALS FROM COVID-19 IS CLEAR AND URGENT Assessing the risk and costs of COVID-19 in Impact of COVID-19 on immunocompromised immunocompromised populations in a large United States populations during the Omicron era: insights from the 2 1 commercial insuranc
Slide 6: VYD222 Has Demonstrated Broad In Vitro Neutralizing Activity Against Variants
VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIOUS PRE-OMICRON AND OMICRON VARIANTS 1 VARIANT SUBLINEAGE VYD222 WT(D614G) WT(D614G) ✓ Delta B.1.617.2 ✓ BA.1 ✓ BA.4/5 ✓ BA.4.6 ✓ BF.7 ✓ Omicron XBB.1 ✓ XBB.1.5 ✓ XBB.1.5.10 and EG.5 (one of the dominant variants in the U.S.) a
Slide 7: CANOPY Phase 3 Clinical Trial of VYD222 Designed to Rapidly Generate Clinical Data
THE CANOPY PHASE 3 CLINICAL TRIAL OF VYD222 IS DESIGNED TO RAPIDLY GENERATE CLINICAL DATA FOR A POTENTIAL EUA The CANOPY clinical trial is now fully enrolled VYD222 4500 mg IV (n=300) COHORT A Open Label Immunocompromised // (N=300) Day 1 Day 28 Month 3 Month 12 (Dosing) (Primary (Redosing) (Last vi
Slide 8: Significant Market Opportunity With >9M Immunocompromised People in the U.S.
SIGNIFICANT MARKET OPPORTUNITY WITH >9M IMMUNOCOMPROMISED PEOPLE AT INCREASED RISK FOR SEVERE COVID-19 IN THE U.S. Estimated U.S. total addressable market (TAM) • Of the estimated 485K High immunocompromised people at highest risk: 485K – 67K: stem cell transplants 2M – 86K: solid organ transplants
Slide 9: Commercialization Preparations Are Underway for Potential VYD222 Launch
COMMERCIALIZATION PREPARATIONS ARE UNDERWAY FOR POTENTIAL VYD222 LAUNCH IN THE U.S., IF AUTHORIZED Go-to-market planning (e.g., market research, market sizing/segmentation, brand strategy, field force sizing) Market access activities (e.g., payer/pricing research, distribution channels) Manufacturin
Slide 10: Key Q3 2023 Financials
KEY Q3 2023 FINANCIALS Expected cash runway remains into Q4 2024, Cash, cash equivalents and marketable excluding potential contribution from commercial securities were $264.9 million as of product revenue if a mAb candidate is September 30, 2023 authorized or approved mAb: monoclonal antibody 10
Slide 11: Invivyd
INVIVYD My | Hy | \k | m mit cil